EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

DORA : 48‐week weight and metabolic changes in Black women with HIV , in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy

Joana Woods iD, Simiso Sokhela, Godspower Akpomiemie, Bronwyn Bosch, Karlien Möller, Esther Bhaskar, Chelsea Kruger, Ncomeka Manentsa, Noxolo Tom, Philadelphia Macholo, Nomathemba Chandiwana, Andrew Hill und 2 weitere

HIV Medicine · 2025-01 · 26 (1) · 81-96

DOI: 10.1111/hiv.13711 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift HIV Medicine, online erschienen am 17.09.2024. Verfasst von Joana Woods und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Benzoxazines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Treatment‐related weight gain and metabolic complications with antiretroviral integrase‐based regimens, especially among Black women, suggest the need for alternative options.

Methods

We conducted a 48‐week, open‐label, single‐arm, single‐centre, phase IIIb switch study to evaluate the tolerability, safety and efficacy of switching from stable efavirenz‐ or dolutegravir‐based antiretroviral therapy to doravirine/lamivudine/tenofovir disoproxil fumarate in Black women.

Results

The 101 participants enrolled (median age 35 years; interquartile range 31–40) were on efavirenz ( n = 46; mean duration on therapy 1.7 years) or dolutegravir‐based ( n = 55; mean duration 1.5 years) antiretrovirals at screening. Retention at 48 weeks was 92/101 participants, and viral suppression was >90% throughout the study, with a single case of doravirine resistance (106 M, V108I and H221Y mutations). The mean weight percentage change at week 48 was 4.7% (95% confidence interval [CI] 3.0–6.5; p < 0.001), and the adjusted mean change was 2.7 kg (95% CI 1.50–3.98; p < 0.001); for efavirenz, the percentage change was 5.0% (95% CI 2.9–7.1; p < 0.001), and the adjusted weight gain was 3.5 kg (95% CI 1.93–5.13); for dolutegravir, the percentage change was 4.5% (95% CI 1.8–7.3; p < 0.001), and the adjusted weight gain was 2.1 kg (95% CI 0.26–3.90). Statistically significant decreases in lipid panel percent mean to week 48 included: total cholesterol −8.4% (95% CI −11.3 to −5.5; p < 0.001), triglycerides −10.4% (95% CI −16.4 to −4.4; p < 0.001) and high‐density lipoprotein −14.8% (95% CI −18.5 to −11.2%; p < 0.001), with minor differences when disaggregating the mean percent change in lipids between previous efavirenz/dolutegravir regimens. Adverse events due to doravirine were few and mild.

Conclusions

Our findings suggest that a switch to doravirine from efavirenz or dolutegravir is safe and effective in Black women, with significant improvement in lipid profiles, but does not arrest progressive weight gain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHeterocyclic Compounds, 3-RingHIV InfectionsBenzoxazinesWeight GainTriazolesAnti-HIV AgentsHumansFemaleAdultCyclopropanesPiperazinesAlkynesOxazinesLamivudineBlack or African AmericanTenofovirViral LoadDolutegravir

Stichwörter der Autor:innen

antiretroviralblackdoravirinefemalemetabolic

Substanzen

PyridonesHeterocyclic Compounds, 3-RingCyclopropanesPiperazinesAlkynesOxazinesBenzoxazinesTriazolesAnti-HIV AgentsLamivudine

Autor:innen und Institutionen

  • Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Department of Public Health Medicine, School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

ORCID-Profile: Joana Woods, Willem D F Venter

Förderung

  • MSD Sharp and Dohme

Zitieren

APA

Woods, J., Sokhela, S., Akpomiemie, G., Bosch, B., Möller, K., Bhaskar, E., Kruger, C., Manentsa, N., Tom, N., Macholo, P., Chandiwana, N., Hill, A., Moorhouse, M., & Venter, W. D. F. (2025). DORA : 48‐week weight and metabolic changes in Black women with HIV , in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy. HIV Medicine, 26(1), 81-96. https://doi.org/10.1111/hiv.13711

Vancouver

Woods J, Sokhela S, Akpomiemie G, Bosch B, Möller K, Bhaskar E, et al. DORA : 48‐week weight and metabolic changes in Black women with HIV , in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy. HIV Medicine. 2025;26(1):81-96. doi:10.1111/hiv.13711

BibTeX
@article{Woods2025,
  author = {Woods, Joana and Sokhela, Simiso and Akpomiemie, Godspower and Bosch, Bronwyn and Möller, Karlien and Bhaskar, Esther and Kruger, Chelsea and Manentsa, Ncomeka and Tom, Noxolo and Macholo, Philadelphia and Chandiwana, Nomathemba and Hill, Andrew and Moorhouse, Michelle and Venter, Willem D F},
  title = {DORA : 48‐week weight and metabolic changes in Black women with HIV , in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy},
  journal = {HIV Medicine},
  year = {2025},
  volume = {26},
  number = {1},
  pages = {81--96},
  doi = {10.1111/hiv.13711}
}
Kostenlos starten →